HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Study Finds Voltaren Is Analgesic Of Choice For Elderly Germans

Executive Summary

As GSK's Voltaren celebrates its 20th anniversary, the OTC analgesic brand remains as popular as ever with elderly Germans, according to a new study by the firm. 

You may also be interested in...



Winners In CHPA’s First OTC Marketing Awards Include Perrigo, J&J, GSK

CHPA awarded five grand prize winners from more than 40 consumer health companies entered in its first US OTC Marketing Awards. Perrigo won for “Best OTC Corporate Social Responsibility Campaign” and a J&J Tylenol campaign honoring caregivers was named “Best OTC Digital Campaign.”

Sweden Reverse-Switches Diclofenac Over Cardio Fears

Oral diclofenac will no longer be available without a prescription in Sweden after the national drug regulator judged that the potential adverse event risks were too high to justify continued OTC supply. Products from GSK and Mylan will be affected by the decision.

GSK Plans Further Divestments As Pfizer Brands Drive Up Q3 Sales

GSK is plotting further divestments into next year as it looks to focus its portfolio on key categories and raise funds to cover the costs of integrating Pfizer's Consumer Healthcare business. In the third quarter, GSK's sales advanced double-digits thanks to the inclusion of Pfizer megabrands like Advil and Centrum.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel